Amarin has appointed Mark Salyer to the newly-created position of chief commercial officer.
He joins the Irish biopharma company from Teva, where he served as general manager of its US respiratory division, and prior to that he held senior roles at GlaxSmithKline and Altana.
Amarin’s president and CEO John Thero said: “Mark brings a strong track record of success coupled with valuable experience and proven leadership to our management team to help drive our anticipated expansion.
“We expect Mark’s driven, people-oriented, hands-on approach to work well with our existing commercial organisation to help build on our growth.”
Salyer’s appointment comes at a key juncture for Amarin as it awaits next year’s publication of results from the REDUCE-IT cardiovascular outcomes trial. The 8,000-patient study involves its first FDA-approved product, the omega-3 fatty acid-based Vascepa.